To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 246 participants.

Also called NCT01068860

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 246 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01068860
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Canada, Finland, Germany, India, Italy (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01068860. Randomized; quadruple masking; primary purpose treatment. Start 2010-02 (registry gives no type); primary completion 2010-08 (actual). Results posted on 2011-09-05.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies
Condition
Type 2 Diabetes Mellitus
Condition
Impaired Glucose Tolerance
Intervention (Drug)
Canakinumab 150 mg
Intervention (Drug)
Placebo to Canakinumab
Lead sponsor
Novartis (class: industry)

Record details

Record id
cardio:ct-nct01068860
Content hash
4bb054b5254b92efdae87ccfd5e053ef05a3fd7def934ca49cbde720afbe04d8